Quantcast

Research Commercialisation: The Road to Economic Recovery and Growth

March 18, 2014

LONDON, March 18, 2014 /PRNewswire/ –

UK government, leading industrial, investor and academic speakers to review strategies
to support the commercialisation of academic research at a new Elsevier conference

“Research Commercialisation: From Ideas to IPO”: 19-20 May 2014, London,
UKhttp://www.idea2ipo-conference.com

With high expectations of a return on government and public investment in academic
research regarding job creation and economic growth, the pressure for sustained success
has increased exponentially in the past five years. In that context, Elsevier
[http://www.elsevier.com ], a world-leading provider of scientific, technical and medical
information products and services, today announced a new thought-leadership event about
the most effective ways to enhance the commercialisation of university-owned intellectual
property.

“Research Commercialisation: From Ideas to IPO” (19-20 May 2014, London, UK
http://www.idea2ipo-conference.com) will provide an international forum for knowledge
transfer that will enable different sectors to develop new government- university-industry
-investor collaborations. Thought leaders representing a wide range of government,
academic, and industrial experts all of whom understand the necessity for an international
partnering platform, will address what has worked, what has failed, and concrete steps to
improve global economic innovation and job creation. Together they will explore ways to
translate entrepreneurial innovations into economic growth.

Amanda Brooks [http://www.idea2ipo-conference.com/bio-brooks.html ], Director for
Innovation within the UK government Department for Business, Innovation and Skills (BIS),
will give the keynote presentation. Other key speakers include:

        - Lidia Borrell Damian
          [http://www.eua.be/about/who-we-are/secretariat/lidia-borrell-damian.aspx ], Director
          Research and Innovation, European University Association, Belgium
        - Kevin Cullen [http://www.kca.asn.au/about-us/meet-the-team/kevin-cullen ],
          CEO, New South Innovations Pty Limited, University of New South Wales, Australia
        - Sean Flanigan,
          [http://www.autm.net/AM/Template.cfm?Section=Board_Members&Template=/CM/ContentDisplay.cfm&ContentID=10504 ]
          Immediate Past President, AUTM, USA
        - David Sweeney
          [http://www.research-europe.com/index.php/2013/12/david-sweeney-director-of-research-innovation-and-skills-higher-education-funding-council-for-england ]
          , Director,
          Research, Innovation and Skills, Higher Education Funding Council for England, UK

Speakers will provide topical insight and real world examples of the challenges,
risks, and opportunities associated with entrepreneurial projects that commercialise
university-owned intellectual property. In addition to traditional information exchange,
an online partnership system for delegates will be implemented to build connections and
foster future collaborations.

Commercialisation of research and technology as a route to economic growth

Universities are a major driver of the British economy. In 2011-12, they contributed
GBP3.4 billion through business services including commercialisation of new knowledge,
delivery of professional training and consultancy, according to findings by the Higher
Education Business and Community Interaction Survey
[http://www.hefce.ac.uk/pubs/year/2013/201311 ].

This report prompted the British government to invite Sir Andrew Witty, CEO of
GlaxoSmithKline and Chancellor of the University of Nottingham, to undertake an
independent review “to explore how universities can support growth by working with
organizations such as Local Enterprise Partnerships (LEPs), responsible for setting
strategies to drive economic growth across the country.” The Witty Review
[https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/249720/bis-13-1241-encouraging-a-british-invention-revolution-andrew-witty-review-R1.pdf ]
, which
Elsevier’s Research Intelligence
[http://www.elsevier.com/online-tools/research-intelligence ] team helped produce, was
released on October 17. Ten recommendations are made (page 6) to the British government,
many of which will be discussed at the conference.

Additionally, a recent report for the UK Department for Business, Innovation and
Skills
[https://www.gov.uk/government/publications/performance-of-the-uk-research-base-international-comparison-2013 ]
, showed the UK remains a global research heavyweight. While the UK
represents just 0.9% of the global population, it accounts for 3.2% of R&D expenditure,
4.1% of researchers, 6.4% of research articles, 9.5% of research article downloads and
15.9% of the world’s most highly-cited articles. The report, also supported by Elsevier’s
Research Intelligence, showed the important role that cross-disciplinary collaboration
plays in solving complex research problems, another key conference theme.

“We want students, faculty, business leaders, policy makers, entrepreneurs and
investors to engage in a way that inspires new projects and builds sustainable
relationships,” said Dr. Lily Khidr, Program Chair, and a publisher at Elsevier. “We have
brought together a dynamic group of international keynote speakers and panel sessions to
achieve this.”

Early registration deadline is April 7, 2014. For more information, go to:

http://www.idea2ipo-conference.com/conference-register.html

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and 25,000 book titles,
including major reference works from Mosby and Saunders. Elsevier’s online solutions
include ScienceDirect [http://www.sciencedirect.com ], Scopus [http://www.scopus.com ],
SciVal [http://info.scival.com ], Reaxys [http://www.elsevier.com/reaxys ], ClinicalKey
[https://www.clinicalkey.com ] and Mosby’s Suite [http://www.confidenceconnected.com ],
which enhance the productivity of science and health professionals, helping research and
health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world leading provider of professional information
solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly
owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

        Media Contact
        Iris Kisjes
        Senior Manager Corporate Relations, Elsevier
        +31-20-485-3072
        I.Kisjes@elsevier.com

SOURCE Elsevier


Source: PR Newswire



comments powered by Disqus